In Reply We agree with the comments made by Viansone and colleagues and appreciate that they have brought to our attention the results of Liu et al,1 who have shown similar results to ours.2 In the study by Liu et al,1 patients with colon cancer with at least 1 low-affinity allele (FCGR2A-131R) had improved overall survival compared with patients with only high-binding alleles (FCGR2A-131H). Although we did not see this same result for the FCGR2A-131H/R alleles, we did observe that patients who had only the low-binding allele (158F) for FCGR3A had a better prognosis than patients with 1 or more high-binding alleles (FCG3A-158V) among patients with breast cancer included in the chemotherapy arm of NSABP clinical trial B-31. The prognostic effect associated with FCGR2A in colon cancer and FCGR3A in breast cancer may be a result of the different types of immune reactions that result from breast and colon cancer, although this explanation is purely speculative.